20,800 Shares in Guardant Health, Inc. (NASDAQ:GH) Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp purchased a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 20,800 shares of the company's stock, valued at approximately $635,000.

Other hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Guardant Health during the fourth quarter worth $26,000. SBI Securities Co. Ltd. purchased a new stake in Guardant Health during the 4th quarter worth $43,000. Kimelman & Baird LLC acquired a new position in Guardant Health in the 4th quarter worth $58,000. NewEdge Advisors LLC boosted its position in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after buying an additional 230 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in Guardant Health in the 4th quarter valued at about $80,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Stock Down 0.1%

GH stock traded down $0.04 during midday trading on Thursday, reaching $37.05. The company had a trading volume of 1,482,951 shares, compared to its average volume of 2,167,665. The firm has a market capitalization of $4.59 billion, a PE ratio of -10.41 and a beta of 1.49. The stock has a 50 day moving average price of $43.62 and a 200 day moving average price of $39.87. Guardant Health, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business's revenue was up 20.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.46) EPS. Research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Buying and Selling at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the transaction, the chief executive officer now directly owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 107,132 shares of company stock worth $5,248,393. 6.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

GH has been the topic of a number of analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $60.00 target price (up from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. TD Securities raised their price objective on Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Stifel Nicolaus upped their target price on Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Canaccord Genuity Group raised their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Finally, UBS Group lifted their price target on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $52.32.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.